|Articles|January 15, 2003
- BioPharm International-01-01-2003
- Volume 16
- Issue 1
Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies
Author(s)Jill Wechsler
by Jill Wechsler Manufacturers are concerned about congressional efforts to establish a Medicare pharmacy benefit and to regulate research while FDA shifts regulation of biologics and other drugs.
Advertisement
Articles in this issue
almost 23 years ago
Biotech World: Canada's Supreme Court says "No" to Harvard Mousealmost 23 years ago
Guest Editorial: At the Governance Crossroadalmost 23 years ago
Reducing Costs by Facility Designalmost 23 years ago
Guidelines for Optimization and Scale-Up in Preparative Chromatographyalmost 23 years ago
Survival Strategies: Board Compensation Changing with the TimesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
2
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
5
